Comparable Incidence of Pneumonia Across Treatment Groups

PLA SAL50 FP250 FP500 FSC250/50 FSC500/50

Pneumonia n=576 n=341 n=399 n=391 n=178 n=169

Adverse Events 7 2 7 10 0 2 (1.2%) (0.6%) (1.8%) (2.6%) (1.2%)

Serious Adverse 3 2 5 7 0 2Events (0.5%) (0.6%) (1.3%) (1.8%) (1.2%)

Previous slide

Next slide

Back to first slide

View graphic version